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ABSTRACT
The concept that solid tumors are maintained by a productive interplay between
neoplastic and non-neoplastic elements has gained traction with the demonstration that
stromal fibroblasts and immune system cells dictate cancer development and progression.
While less studied, brain tumor (glioma) biology is likewise influenced by non-neoplastic
immune system cells (macrophages and microglia) which interact with neoplastic glioma
cells to create a unique physiological state (glioma ecosystem) distinct from that found
in the normal tissue. To explore this neoplastic ground state, we leveraged several
preclinical mouse models of neurofibromatosis type 1 (NF1) optic glioma, a low-grade
astrocytoma whose formation and maintenance requires productive interactions between
non-neoplastic and neoplastic cells, and employed whole tumor RNA-sequencing and
mathematical deconvolution strategies to characterize this low-grade glioma ecosystem
as an aggregate of cellular and acellular elements. Using this approach, we demonstrate
that optic gliomas generated by altering the germline Nf1 gene mutation, the glioma
cell of origin, or the presence of co-existing genetic alterations represent molecularlydistinct tumors. However, these optic glioma tumors share a 25-gene core signature,
not found in normal optic nerve, that is normalized by microglia inhibition (minocycline),
but not conventional (carboplatin) or molecularly-targeted (rapamycin) chemotherapy.
Lastly, we identify a genetic signature conferred by Pten reduction and corrected by
PI3K inhibition. This signature predicts progression-free survival in patients with either
low-grade or high-grade glioma. Collectively, these findings support the concept that
gliomas are composite ecological systems whose biology and response to therapy may
be best defined by examining the tumor as a whole.

INTRODUCTION

by the productive interactions between these diverse
cellular and acellular elements, the concept of a cancer
ecosystem has been advanced [2–4]. In support of this
concept, non-neoplastic stromal cells, such as fibroblasts
and immune system cells, have been shown to drive solid
tumor development and progression [5, 6]. Within the
central nervous system, brain tumor (glioma) growth in
experimental mouse models is similarly controlled by
specific monocyte populations, including microglia and
macrophages, that are recruited by the tumor cells through
the elaboration of chemokines, like colony stimulating

Histological examination of most solid tumors
reveals that these cancers are composed of numerous
distinct cell types, which are embedded in a rich
extracellular matrix containing growth factors and
cytokines. Among the cell types in these tumors are
differentiated and stem-like neoplastic cells, as well as
non-neoplastic cells, such as monocytes, fibroblasts,
and endothelial cells [1]. With the recognition that the
biological behaviors of many solid cancers are dictated
www.impactjournals.com/oncotarget
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RESULTS AND DISCUSSION

factor 1 (CSF-1) [7]. Additionally, productive interactions
between monocytes and glioma cells create a feed-forward
paracrine circuit that perpetuates high-grade glioma
growth [8–10]. These studies in high-grade malignancies
have suggested alternative approaches to cancer treatment,
in which targeted therapies against stromal cell types or
signals might emerge as a potential adjuvant approaches
[11–15].
One of the clinical situations where stromal therapies
might be particularly useful is in the treatment of pediatric
low-grade tumors. Unlike adult high-grade malignancies,
these tumors are slow growing (with proliferative indices
often less than 1%) and arise in children whose brains are
still developing. Therapies that target unique elements
of the tumor ecosystem, not shared by the developing
brain, would be highly desirable. This issue is well
illustrated by the Neurofibromatosis type 1 (NF1) cancer
predisposition syndrome, in which affected children are
prone to the formation of low-grade nervous system
tumors (peripheral nerve sheath tumors and optic pathway
gliomas). Examination of these tumors reveals prominent
immune system infiltration and interdependencies
between neoplastic and non-neoplastic cell types [16–22].
Specifically, the formation and continued growth
(maintenance) of low-grade optic gliomas in mice
require a supportive tumor microenvironment containing
microglia, which are attracted to the developing cancer
by chemokines [20], and elaborate specific growth
factors that promote neoplastic cell growth [19]. These
cellular interactions could be hypothesized to create a
new homeostatic state, not present in the non-neoplastic
optic nerve, and thus establish new circuitries and
interdependencies for chemotherapeutic targeting.
In the current study, we employed whole-tumor
RNA-sequencing and mathematical deconvolution
strategies using preclinical mouse models of Nf1 optic
glioma to characterize the tumor ecosystem as an
aggregate gene expression pattern distinct from the healthy
optic nerve. Leveraging numerous different murine optic
glioma genetically-engineered mouse (GEM) models, we
found that histologically-similar tumors are molecularly
distinct. However, despite their uniqueness, all Nf1 murine
optic gliomas examined share a 25-gene expression
signature that distinguishes tumor tissue from normal optic
nerve. This core genetic signature was minimally affected
by conventional (carboplatin) or biologically-targeted
(rapamycin) therapy, but was normalized following
minocycline treatment, which inhibits tumor-associated
microglia function. Lastly, we discovered a PTEN/PI3Kdriven molecular signature that correlates with the overall
survival of patients with either low-grade or high-grade
glioma. Taken together, our study suggests that shared and
unique whole-tumor gene expression patterns may serve
as biomarkers of tumor response to therapy and patient
survival.

www.impactjournals.com/oncotarget

Whole tumor RNA-sequencing of a diverse
collection of Nf1 optic glioma tumors reveals
molecularly-distinct neoplasms
In an effort to accurately represent the heterogeneity
inherent in human NF1-associated optic pathway glioma
(NF1-OPG), we have previously engineered mice that
differ with respect to the germline Nf1 gene mutation
(null allele (FMC) [23] versus NF1 patient germline
NF1 gene mutation; R681* (F18C) [24]), the cell of
origin (GFAP+ neuroglial progenitors (FMC) [23] versus
Olig2+ progenitor cells (FMOC) (Solga A, manuscript
in preparation)), and the presence of a co-existing
heterozygous Pten deletion in the tumor cells (FMPC)
[25, 26]. Using these four optic glioma strains, we
performed whole tumor RNA-Seq on 27 specimens along
with four normal age- and sex-matched optic nerves. Gene
expression heatmap representation of all 31 samples across
4,624 genes revealed differentially-expressed gene sets in
at least one pairwise comparison relative to normal optic
nerve, as well as between Nf1 GEM optic glioma models
(Figure 1A). While some sample-to-sample heterogeneity
was found between whole tumor specimens from the same
GEM model, significantly larger differences among the
four models were demonstrated by the average profiles
(Figure 1B). Because these expression profiles were from
homogenized whole tumor tissue, the observed molecular
differences between models likely reflect contributions
from multiple distinct cell types. However, despite clear
differences in tumor latency, proliferative rates, and tumor
volumes, immunohistochemical analyses of these tumors
revealed only slight differences in the percentages of
microglia (Iba1+ cells), astroglial (GFAP+ or S100β+ cells),
or Olig2+ progenitor cells [23–25].
To better understand the murine Nf1 optic glioma
ecosystem as a whole, we next sought to estimate the
cell type-specific contributions to the observed gene
expression differences. In previous studies, we and others
have used computational approaches to deconvolve the
data into potential cell type profiles. Whole transcriptome
deconvolution requires two basic inputs - genomewide transcript abundances and a measure of cellular
composition - both of which can be derived from RNA-Seq
data. As demonstrated in our previous study, in which we
applied deconvolution to human high-grade gliomas, we
can use the abundance of a cell type-specific marker or set
of markers for each cell type in any given tissue to estimate
the fractional composition of each cell type [27, 28].
Hence, we are able to use the RNA expression levels of
cell type-specific marker genes in the composite profiles
of each specimen to solve for an estimated abundance of
each gene in each cell type by least-squares regression.
While this approach assumes that cell type-specific RNA
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abundances are invariant across specimens, the fitting
procedure allows us to restrict our analysis to genes with
expression patterns that are fit well by this model.
For these analyses, we specifically focused
on glial cell populations (microglia and macroglia
[oligodendrocytes,
astrocytes,
oligodendrocyte
precursors]; Figure 1C–1F). As such, the glial cell typespecific contributions for genes that are differentially
expressed (padj<0.01, |log2(fold-change)| > 1) between
each Nf1 GEM optic glioma model and normal optic
nerve can be represented, as estimated by computational
deconvolution. Using this approach, several important
observations were made: First, all of the Nf1 GEM optic
glioma models showed significant depletion of genes
specific to mature oligodendrocytes compared to normal
optic nerve (FF). Second, while all four models exhibited
enrichment of oligodendrocyte progenitor cell (OPC)
gene expression, this finding was most pronounced in
the FMOC and FMC optic glioma models relative to the
F18C and FMPC optic glioma models. Third, the largest
distinction between the FMPC optic glioma model and
the normal optic nerve was enrichment of astrocyte gene
expression. This result suggests that Pten reduction, which
is the only genetically-engineered difference between the
FMC and FMPC optic glioma models, may alter the glial

lineage character of the tumor. However, these changes in
gene expression did not correlate with changes in Olig2+,
NG2+ or GFAP+ cell numbers between Nf1 GEM optic
glioma strains ([24, 25]; Supplementary Figure 1). The
apparent disconnect between glial cell-estimated gene
expression and actual glial cell numbers suggests that these
differentially-expressed gene signatures reflect global
changes in the tumor ecosystem, rather than alterations
in overall tumor cellular composition. Moreover, analysis
of previously-acquired RNA-sequencing data from FMC
tumor-associated microglia relative to those from Nf1+/mice [19] demonstrated that the differentially-expressed
genes assigned to microglia by deconvolution were not
similarly altered in the actual microglia from these tumors
(data not shown). Collectively, these results support the
notion that the gene expression patterns in the tumor do
not reflect the individual contributions of each cell type,
but rather the composite interactions of all cell types.

All Nf1 optic glioma GEM models share a core
gene expression signature that is minocyclinesensitive
While Figure 1 highlights the molecular differences
among the four different Nf1 optic glioma models, all of

Figure 1: (A) Heatmap of RNA-Seq expression z-scores computed for all genes that are differentially expressed (padj < 0.01, |log2(fold-

change)| > 1) between all pairwise comparisons of the optic glioma models and the healthy optic nerve (FF) controls. Each column in the
heatmap is an individual sample. (B) Same as (A), but averaged over all samples for each genotype. (C) Computational deconvolution of
cell type-specific gene expression for genes that are differentially expressed between FMOC tumors and FF controls. In the top panel, each
row in the heatmap corresponds to a specific differentially-expressed gene and each column corresponds to a cell type. The lower panel
shows the aggregate expression in each cell type for all genes that are high in FMOC or FF tumors. The analysis shows that the FMOC
tumors are highly enriched in OPC-like gene expression. (D) Same as (C), but for differentially-expressed genes from the comparison of
FMC tumors to FF controls. Similar to FMOC, the FMC tumors are also dominated by an OPC-like gene expression pattern. (E) Same as
(C), but for differentially-expressed genes from the comparison of F18C tumors to FF controls. The F18C tumors have both higher OPClike and astrocytic gene expression relative to FF controls. (F) Same as (C), but for differentially-expressed genes from the comparison
of FMPC tumors to FF controls, demonstrating a more pronounced astrocytic gene expression in FMPC gliomas. OPC, oligodendrocyte
progenitor cell; Astro, astocyte; Oligo, oligodendrocyte.
www.impactjournals.com/oncotarget
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Table 1: Genes comprising the 25-core signature in all optic glioma models
Gene

Name

Aldh1l1
Btbd3
Btbd17
Cd38
Cspg5
Cxcl14
Elmo2
Etv5
Fabp5
Fgfrl1
Gja1
Igdcc4
Marcks
Ncan
Ntsr2
Pcdhgc3
Pygm
S1pr1
Sdc3
Sfxn5
Shc3
Slc6a11
Spry4
Tril
Wnt7b

aldehyde dehyrogenase 1 family member L1
BTB (POZ) domain-containing 3
BTB (POZ) domain-containing 17
CD38
chondroitin sulfate proteoglycan 5 (Caleb)
C-X-C motif chemokine ligand 14
engulfment and cell motility 2
ets variant 5 (Erm)
fatty acid binding protein 5 (E-Fabp)
fibroblast growth factor receptor-like 1
gap junction protein, alpha 1 (connexin-43)
immunoglobulin superfamily DCC subclass member 4 (Nope)
myristoylated alanine-rich protein kinase C substrate
neurocan (Cspg3)
neurotensin receptor 2
protocadherin gamma subfamily C, 3
glycogen phosphorylase, muscle associated
sphingosine-1-phosphate receptor 1 (Edg1)
syndecan 3
sideroflexin 5
SHC adaptor protein 3 (N-Shc)
solute carrier family 6 member 11 (Gat3)
sprouty homolog 4
TLR4 interactor with leucine-rich repeats
wingless-type MMPTV integration site family, member 7B

these tumors shared a core gene expression signature.
In this regard, we identified a 25-gene signature that is
universally differentially expressed (increased) relative to
normal optic nerves across the 27 optic glioma specimens
(Table 1; Figure 2A). Interestingly, this signature was
most pronounced in the FMOC and FMC tumors and
relatively diminished in the FMPC tumors. Accordingly,
our deconvolution model suggests that these genes are
predominantly associated with OPC-like cells. While
there are more GFAP+ cells in all Nf1 optic glioma models
relative to the non-neoplastic optic nerve, there are only
small differences in the relative proportions of Olig2+,
GFAP+, or NG2+ glial cells between the various GEM
models ([24, 25]; Supplementary Figure 1). In addition,
GO-term analysis of the core genes did not reveal
enrichment in specific categories (data not shown). As
before, we favor the interpretation that this core signature
represents a “neoplastic state” gene expression network
established by the glioma ecosystem. Since this core gene
expression signature distinguishes normal from tumorbearing optic nerve, we hypothesize that it might be used
www.impactjournals.com/oncotarget

to identify brain tumor treatments that best normalize the
glioma ecosystem.
To explore this idea further, we leveraged prior
preclinical studies from our laboratory in which
conventional and biologically-targeted chemotherapy
agents were evaluated prior to clinical translation. While
our previous preclinical experiments demonstrated that
temozolomide (TMZ) is effective at inducing tumor
death [29], we now employed carboplatin as a standard
chemotherapy reference, as it is the first line therapy
for children with NF1-OPG [30, 31]. Similar to that
observed in FMC mice following TMZ treatment,
carboplatin induced a significant reduction in both tumor
volume and proliferation (%Ki67+ cells; Figure 2B).
Additionally, we evaluated the effect of two biologicallytargeted therapies previously shown to inhibit mouse
Nf1 optic glioma growth in vivo. We selected rapamycin
(mechanistic target of rapamycin [mTOR] inhibitor; [29])
and minocycline (microglia inhibitor; [17]) to inhibit
neoplastic and stromal cell function, respectively, in
separate experiments.
52477
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Overall, we found that rapamycin treatment resulted
in very few changes in the 25-core gene expression profile
compared to carboplatin and minocycline. This result is
not surprising in light of recent clinical studies on a related
NF1-associated benign tumor, the plexiform neurofibroma,
in which rapamycin analogs exhibited little clinical efficacy
[32, 33]. Importantly, while carboplatin treatment clearly
inhibited tumor growth in vivo, there was also little effect
on the 25-core gene expression signature. This finding
suggests that this time-tested chemotherapy may not
normalize the tumor ecosystem. In this regard, tumor
shrinkage is observed in the minority of children with
NF1-OPG [34, 35], and, when observed, is often relatively
modest or not longstanding (durable response) [36–38].
While neither anti-neoplastic cell therapy
normalized the optic glioma core signature, minocycline
treatment resulted in downregulation of this 25-core gene
signature in the majority of mice (Figure 2C). Furthermore,
analysis of the entire set of genes that were normalized
by minocycline treatment using our deconvolution model

showed that these alterations were largely associated
with OPC-like cells, rather than microglia (Figure 2D).
These results imply that blocking microglia function
with minocycline has its greatest impact on the tumors
themselves. This finding is consistent with recent RNAsequencing studies on Nf1 optic glioma-associated
microglia, in which one chemokine (CCL5) made by
these microglia positively regulates both microglia
recruitment and glioma growth [19]. Future studies
aimed at normalizing the tumor microenvironment using
stroma-targeted treatments may prove most effective at reestablishing a normal tissue ecosystem, and result in more
durable glioma responses in human clinical trials.

A PTEN/PI3K-dependent gene signature is
associated with poor glioma prognosis
As noted above, Pten deletion altered both the
lineage resemblance and core signature expression of
the FMC optic glioma model. Heat map representation

Figure 2: (A) Heatmap of RNA-Seq expression z-scores computed for the 25-gene core signature that is commonly differentially
upregulated across all optic glioma models. (B) FMC mice treated with carboplatin at 3 months of age, and analyzed 1 month later, reveals
decreased tumor volumes and percentages of Ki67+ cells. Control mice were treated with vehicle only and processed identically. *p < 0.05.
Scale bar, 100 μm. (C) Same as (A), but for minocycline-treated and untreated FMC gliomas and FF controls. (D) Deconvolution of genes
that are normalized in FMC by minocycline (highly or lowly expressed in FMC gliomas vs. FF controls, but either decreased or increased,
respectively, by minocycline treatment).
www.impactjournals.com/oncotarget
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(Figure 3A) and deconvolution profiles (Figure 3B)
revealed a differentially-expressed gene signature between
FMC and FMPC specimens (Table 2). In the latter analysis,
genes associated with the FMC and FMPC models were
enriched in OPC-like and astrocytic gene expression,
respectively. Importantly, these differentially-expressed
signatures were not reflected in the relative abundance of
either OPCs or astrocytes (Supplementary Figure 1).
Because PTEN is a negative regulator of PI3K/
AKT signaling and Nf1 optic glioma growth [25] we
hypothesized that pharmacologic inhibition of PI3K might
normalize this differentially-expressed gene signature in
FMPC mice. The ability of a PI3K-specific inhibitor,
BKM120, to restore the FMC gene expression pattern
in FMPC mice was revealed by sample-specific and
average expression profiles (Figure 4A, 4B). Consistent
with differential expression of OPC-associated genes in
FMC tumors, deconvolution demonstrated a pronounced
enrichment of OPC-associated genes in FMPC tumors
following treatment with BKM120 (Figure 4C). These
results demonstrate that a PI3K-regulated gene signature
(Table 3) partly accounts for the differences observed
between FMC and FMPC optic gliomas.
Since the heterozygous Pten deletion was restricted to
the neoplastic cells by virtue of the fact that Cre-mediated
Pten reduction was targeted to GFAP transgene-expressing
cells containing somatic Nf1 loss, we sought to determine
whether this signature was maintained in optic glioma
stem cells (o-GSCs) that derived from FMC and FMPC
mouse tumors. Previously, we showed that o-GSCs from
FMC mice are true cancer stem cells, with the ability
to self-renew, undergo multi-lineage differentiation,
(Supplementary Figure 2) and form glioma-like lesions

when transplanted into naïve mice [39]. RNA-seq was
performed using independent isolates of o-GSCs from at
least three pools of FMC and FMPC mice (n = 2 mice/
pool). Similar to that observed in the whole tumors, there
was a relative depletion of the BKM120 normalized
signature in FMC versus FMPC o-GSCs (Figure 4D),
supporting a primary effect of heterozygous Pten deletion
on the neoplastic cells in these gliomas. In addition, to
determine whether BKM120 treatment normalizes this gene
signature in purified o-GSCs, we treated separate pools of
o-GSCs derived from FMPC mice with BKM120 in vitro
and observed decreased PI3K/AKT activity (Supplementary
Figure 3). As observed following BKM120 treatment of
FMPC mice, we found the same signature to be significantly
depleted in BKM120 treated o-GSCs relative to vehicletreated controls (Figure 4E). Taken together, the BKM120normalized gene signature behaves similarly in purified
glioma stem cells and glioma tissue from the same models.
One of the clinically-relevant uses of these
differentially-expressed gene signatures is their application
to predicting survival in patients with gliomas. We
first examined the 25-gene core signature, common to
all murine Nf1 optic gliomas, and found that it did not
separate patients with either low-grade or high-grade
gliomas into clinically-relevant subgroups based on overall
survival or progression-free survival (data not shown).
However, in striking contrast, differences in patient
survival were observed using an expression signature
comprised of the top 50 FMPC-associated genes that were
most significantly normalized by BKM120 treatment
(BKM120 normalized signature). For these analyses, gene
set enrichment analysis (GSEA) was employed to assess
the relative expression of this gene signature across human

Figure 3: (A) Heatmap of RNA-Seq expression z-scores computed for genes that are differentially expressed (padj < 0.01, |log2(fold-

change)| > 1) between FMPC and FMC gliomas. (B) Deconvolution of genes that are differentially expressed between FMPC and FMC
gliomas. In the top panel, each row in the heatmap corresponds to a specific differentially expressed gene and in each column corresponds
to a cell type. The lower panel shows the aggregate expression in each cell type for all genes that are high in FMPC or FMC. The analysis
shows that the FMC tumors are highly enriched in OPC-like gene expression compared to FMPC tumors, which are highly enriched in
astrocytic gene expression.
www.impactjournals.com/oncotarget
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Table 2: Genes differentially-expressed between FMC and FMPC optic gliomas
Genes with high expression in FMPC

Name

A4galt

alpha 1,4-galactosyltransferase

Actb

actin, beta

Akap12

A kinase anchor protein 12

Alyref

Aly/REF export factor

Angptl2

angiopoietin-like 2

Anxa11

annexin A11

Cd248
Chrd
Col3a1

CD248 antigen, endosialin
chordin
collagen, type III, alpha 1

Ctgf
Cxcl16
D630003M21Rik
Dbn1

connective tissue growth factor
chemokine C-X-C motif ligand 16
unknown
drebrin 1

Dnaja4

DnaJ heat shock protein family member A4

Dpysl3

dihydropyrimidinase-like 3

Dusp1

dual specificity phosphatase 1

Ehd2

EH-domain containing 2

Gpr81

hydrocarboxylic acid receptor 1

Heyl

hairy/enhancer-of-split related with YRPW motif-like

Hspb1

heat shock protein 1

Htra3

HtrA serine peptidase 3

Kdelr3

Lys-Asp-Glu-Leu endoplasmic reticulum protein retention receptor 3

Krt19

keratin 19

Lama4

laminin, alpha 4

Lgals3
Lmna

galectin 3
lamin A

Loxl1

lysyl oxidase-like 1

Ltbp4

latent transforming growth factor beta binding protein 4

Mmp23

matrix metallopeptidase 23

Msc

musculin

Mvp

major vault protein

Mxra7

matrix-remodeling associated 7

Nbl1

neuroblastoma, suppression of tumorigenicity 1

Ntn1

netrin 1

Pam

peptidylglycine alpha-amidating monooxygenase

Pamr1

peptidase domain containing associated with muscle regeneration 1

Ptrf

polymerase I and transcript release factor

Rab3d

RAB3D, member RAS oncogene family

Rasgef1b

RasGEF domain family, member 1B

Rcn3

reticulocalbin 3, EF-hand calcium binding domain

Rnase1

ribonuclease, RNase A family, 1

Sema3b

sema domain, immunoglobulin domain, short basic domain, secreted, 3B

Serpinh1

serine (or cysteine) peptidase inhibitor, clade H, member 1

Spon2

spondin 2

Stk32c

serine/threonine kinase 32C

Tgfbi

transforming growth factor, beta induced

Tgm2

transglutaminase 2, C polypeptide

Tmem204

transmembrane protein 204

Tubb6

tubulin, beta 6 class V

1500009L16Rik

unknown

Genes with low expression in FMPC

Name

Abat

4-aminobutyrate aminotransferase

Abcd2

ATP-binding cassette, sub-family D (ALD), member 2

Acsbg1

acyl-CoA synthetase bubblegum family member 1

Agl

amylo-1,6-glucosidase, 4-alpha-glucanotransferase

Apba2

amyloid beta precursor protein-binding, family A, member 2

Aqp4

aquaporin 4

Btbd17

BTB (POZ) domain containing 17

Cadm1

cell adhesion molecule 1

Chpt1

choline phosphotransferase 1

Cmip

c-Maf inducing protein

Cntn1

contactin 1

Dmp1

dentin matrix protein 1

Elavl3

embryonic lethal, abnormal vision-like 3

www.impactjournals.com/oncotarget
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Elovl2

elongation of very long chain fatty acids-like 2

Elovl6

ELOVL family member 6, elongation of long chain fatty acids

Frrs1l

ferric-chelate reductase 1 like

Fut9

fucosyltransferase 9

Gabrb1

gamma-aminobutyric acid A receptor, subunit beta 1

Gnaq

guanine nucleotide binding protein, alpha q polypeptide

Gria2

glutamate receptor, ionotropic, AMPA2

Gria4
Grin3a
Gyk

glutamate receptor, ionotropic, AMPA4
glutamate receptor ionotropic, NMDA3A
glycerol kinase

Hsd11b1

hydroxysteroid 11-beta dehydrogenase 1

Itgb8

integrin beta 8

Kcna2

potassium voltage-gated channel, shaker-related subfamily, member 2

Kcnk1

potassium channel, subfamily K, member 1

Luzp2

leucine zipper protein 2

Mdga2

MAM domain containing glycosylphosphatidylinositol anchor 2

Ncan

neurocan

Negr1

neuronal growth regulator 1

Nfia

nuclear factor I/A

Nfib

nuclear factor I/B

Nlgn1

neuroligin 1

Nrxn1

neurexin I

Paqr8

progestin and adipoQ receptor family member VIII

Pcdh15

protocadherin 15

Phka1

phosphorylase kinase alpha 1

Prex2

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2

Ptprd

protein tyrosine phosphatase, receptor type, D

Ptprz1

protein tyrosine phosphatase, receptor type Z, polypeptide 1

Rgs7bp

regulator of G-protein signalling 7 binding protein

Slc1a2
Slc4a4

solute carrier family 1, member 2
solute carrier family 4, member 4

Spag5

sperm associated antigen 5

Timp4

tissue inhibitor of metalloproteinase 4

Tmed5

transmembrane p24 trafficking protein 5

Tmem132b

transmembrane protein 132B

Tmtc2

transmembrane and tetratricopeptide repeat containing 2

Tshz1

teashirt zinc finger family member 1

neoplastic cell compartment (Pten and Nf1 inactivation) can
create differential core signatures that reflect the individual
contributions of these molecular events to the cancer
cells, which can be used to identify prognostic signatures
relevant to patient survival and the potential interpretation
of successful inhibition of the regulated growth control
pathways. Future studies employing these types of
approaches may be instructive, not only for defining
what constitutes tumor, but also for identifying a possible
Achilles heel network node for therapeutic targeting.

low- and high-grade glioma surgical specimens collected
and profiled by The Cancer Genome Atlas (TCGA)
consortium (obtained from the Broad Institute GDAC
Firehose site). In both low-grade (Figure 5A) and highgrade (Figure 5B) glioma, patients with tumors depleted
in the BKM120 treatment signature exhibited significantly
enhanced progression-free survival relative to those with a
PTEN-enriched signature.
Taken together, these data support a model in
which murine Nf1 optic gliomas operate as an ecosystem
composed of a diverse collection of cellular and acellular
elements. The observation that the discovered 25-core
differential gene expression pattern , which distinguishes
tumor from non-neoplastic tissue, does not emanate
from a single cell type (o-GSCs or microglia) argues
that it represents networks of genes that are differentially
expressed as a result of forming a tumor. This new ground
state thus defines glioma at a molecular level, independent
of gross morphological changes or alterations in cell
composition or proliferation. Moreover, the established
glioma gene expression profile provides a platform to
evaluate potential chemotherapeutic agents, either alone
or in combination, for their potential to normalize the
tumor ecosystem and achieve greater treatment responses.
In addition, co-existing genetic mutations targeted to the
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Mice
FF (Nf1flox/flox), FMC (Nf1flox/mut; GFAP-Cre) FMPC
(Nf1
; Ptenflox/wt; GFAP-Cre), F18C (Nf1 gene
mutation c.2041C>T; p.R681X; Nf1flox/R681*; GFAP-Cre)
mice were generated as previously described [23–25].
FMOC mice were generated by intercrossing Nf1flox/
mut mice with Olig2-Cre mice (B6-Olig2tm2 (TVA, cre)Rth/J;
Jackson Laboratory; Nf1flox/mut; Olig2-Cre). All mice were
maintained on a C57Bl/6 background and procedures
performed in accordance with an approved Animal Studies
Committee protocol at Washington University.
flox/mut
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Pharmacological studies

Optic nerve measurements

50 mg/kg/day minocycline (Sigma-Aldrich; PBS,
vehicle) was delivered by intraperitoneal (i.p.) injection
5 days/week for two weeks [17]. 5 mg/kg/day rapamycin
(Selleckchem; 5.2% Tween 80/5.2% polyethylene glycol
400 as vehicle) was administered by i.p. injection 5 days/
week for two weeks [29]. 20 mg/kg/day NVP-BKM120
(Selleckchem; N-methyl-2-pyrrolidone/ polyethylene
glycol 300 (10/90v/v) as vehicle) was delivered by
oral gavage 5 days/week for two weeks [40]. 60 mg/
kg/day carboplatin (Sigma-Aldrich; PBS as vehicle)
was administered by i.p. injection every other day for
1 week. All optic nerves were harvested two weeks
after the initial injection, and processed for RNAseq,
immunohistochemistry and optic nerve measurements as
described below.

Following perfusion with Ringers solution and 4%
paraformaldehyde (PFA), optic nerves were photographed
and volumes measured as previously described [29].

Immunohistochemistry
Optic nerves were microdissected and processed as
described previously [41]. Antibodies used are listed in
Supplementary Table 1.

Cell culture
Optic glioma stem cells (o-GSCs) were isolated
and maintained as previously described [39]. For NVPBKM120 treatments, cells were cultured in neural stem

Figure 4:  (A) Heatmap of RNA-Seq expression z-scores computed for genes that are differentially expressed (padj < 0.01, |log2(fold-

change)| > 1) between FMPC and FMC gliomas across FMC, FMPC, and BKM120-treated FMPC gliomas. Many of the differentially
expressed genes are normalized by BKM120 treatment. (B) Same as (A), but averaged over all samples for each group. (C) Deconvolution
of genes that are differentially expressed between BKM120-treated and untreated FMPC gliomas. In the top panel, each row in the heatmap
corresponds to a specific differentially-expressed gene and in each column corresponds to a cell type. The lower panel shows the aggregate
expression in each cell type for all genes that are high in BKM120-treated and untreated FMPC tumors. The analysis shows that the treated
tumors are highly enriched in OPC-like gene expression (similar to the FMC tumors) compared to the untreated tumors. (C) GSEA showing
enrichment of the 50-gene BKM120 normalization signature in the RNA-Seq profile of FMPC- compared to FMC-derived o-GSCs. (D)
GSEA showing depletion of the 50-gene BKM120 normalization signature in BKM120-treated FMPC-derived o-GSCs compared to
vehicle-treated cells.
www.impactjournals.com/oncotarget
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Table 3: Genes comprising the 50-core signature responsive to BKM-120 inhibition
Gene

Name

Actb
Akr1a1
Aldoa
Alyref
Arf5
Arl4d
Arpc3
Atp6v1f
Cct5
Cd81
Cdc37
Cdr1
Cebpb
Chp2
Cilp
Dpysl2
Dusp1
Dynll1
Eif3d
Ftl1
Fxyd1
Gpr81
Herpud1
Hnrnpl
Ifitm2
Irf2bp2
Kdelr3
Loxl1
Lsp1
Map1lc3b
Mrpl12
Oat
Opalin
Pam
Plat
Plekhf1
Rasgef1b
Rhoc
Slc6a13
Snrpb
Spon2
Sqstm1
Tgfbi

actin, beta
aldo-keto reductase family 1 member A1
aldolase, fructose-biphosphate A
Aly/REF export factor
ADP ribosylation factor 5
ADP ribosylation factor-like GTPase 4D
actin-related protein 2/3 complex subunit 3
ATPase H+ transporting V1 subunit F
chaperonin-containing TCP1 subunit 5
CD81 antigen
cell division cycle 37
cerebellar degeneration related protein 1
CCAAT/enhancer binding protein, beta
calcineurin-like EF-hand protein 2
cartilage intermediate layer protein
dihydropyrimidinase like 2
dual specificity phosphatase 1
dynein light chain LC8-type 1
eukaryotic translation initiation factor 3 subunit D
ferritin light polypeptide 1
FXYD domain-containing ion transport regulator 1
hydroxycarboxylic acid receptor 1
homocysteine inducible ER protein with ubiquitin-like domain 1
heterogeneous nuclear ribonucleoprotein
interferon-induced transmembrane protein 2
interferon regulatory factor 2 binding protein 2
KDEL endoplasmic reticulum protein retention receptor 3
lysyl oxidase like 1
lymphocyte-specific protein 1
microtubule-associated protein 1 light chain 3 beta
mitochondrial ribosomal protein L12
ornithine aminotransferase
oligodendrocytic myelin paranodal and inner loop protein
peptidylglycine alpha-amidating monooxygenase
plasminogen activator, tissue type
pleckstrin homology and FYVE domain containing 1
RasGEF domain family member 1B
ras homolog family member C
solute carrier family 6 member 13
small ribonuclear ribonucleoprotein polypeptides B and B1
spondin 2
sequestosome 1
transforming growth factor, beta-induced
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Tppp3
Tram1
Ubb
Vtn
Wdr1
Ywhaz
1810011O10Rik

tubulin polymerization promoting protein family member 3
translocation-associated membrane protein 1
ubiquitin B
vitronectin
WD repeat domain 1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
unknown

cell medium without EGF and bFGF for 1 hour, followed
by treatment with DMSO (vehicle) or 0.2 µM NVPBKM120 for 5 hours at 37°C, and cells harvested for RNA
isolation or western blotting.

B27, EGF and bFGF for 24 hours at 37°C and fixed
with 4% PFA for immunostaining. o-GSCs were also
differentiated as previously described [39], fixed with
4% PFA, and immunostained with the antibodies listed in
Supplementary Table 1.

Western blotting

RNA extraction and mRNA isolation

Cells were lysed as described previously and
western blotting performed using the antibodies listed in
Supplementary Table 1 [42, 43].

RNA was extracted from Trizol-preserved
tissue and cell lysates using isopropanol precipitation.
Each total RNA sample was re-suspended in 20 uL
of nuclease-free water supplemented with 0.5 U/uL
RNase inhibitor (SUPERaseIN, Life Technologies).
A 5′-biotinylated, LNA-enhanced oligo(dT) capture
probe (Exiqon) was used to isolate poly(A)+ mRNA as
described previously [44].

Immunocytochemistry
o-GSCs were adhered to fibronectin (50 μg/ml)/
poly-D-lysine (10 μg/ml)-coated surfaces and cultured
in neural stem cell medium supplemented with N2,

Figure 5:  Progression-free survival curves for human low-grade gliomas (A) and glioblastomas (B) that are either highly enriched or

depleted of the top 50 genes that are differentially expressed between FMPC and FMC gliomas and most significantly normalized by
BKM120 treatment of FMPC gliomas. Depletion of the 50-gene BKM120 normalization signature is associated with better progressionfree survival in both low-grade (p = 0.015) and high-grade (p = 0.034) human brain tumors.
www.impactjournals.com/oncotarget
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